Skip to main content
. 2024 Dec 10;27(3):644–651. doi: 10.1093/neuonc/noae257

Figure 2.

Figure 2.

KL-50 in TMZ-naïve and post-TMZ MMR-deficient GBM PDX. (A) Survival for mice engrafted with intracranial parental GBM6 PDX and treated with three cycles of vehicle (M-F for 3 consecutive weeks), KL-50 (10 mg/kg), ionizing radiation (2 separate doses of 2.0 Gy), or radiation plus KL-50. (B) Treatment of parental GBM12 PDX with vehicle, KL-50, RT, or RT plus KL-50. *P < 0.05; ****P < 0.0001. (C) In vitro treatment of GBM6R-m185 with vehicle, TMZ, and KL-50. Cell death (left panel) and live cell counts (right panel) are normalized to vehicle-treated cells. (D) IC50 values generated from in vitro cytotoxicity and live cell count assays with TMZ vs KL-50 in GBM6R-m185. (E) Survival for mice engrafted with intracranial GBM6R-m185 and treated with 3 cycles of vehicle, TMZ (10 mg/kg), or KL-50 (10 mg/kg). GBM = glioblastoma; PDX = patient-derived xenograft; RT = radiation therapy; TMZ = temozolomide. *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001.